

Supplementary table 1. Crude and age-specific risk ratios of the most frequent post COVID symptoms among participants

			Vaccinated vs unvaccinated (Infected individuals)								Two doses vaccinated + infected vs uninfected	
			Unadjusted analysis						Adjusted analysis*			
Symptoms and age	Uninfected (n=2447)	Unvaccinated (n=317)	Received one dose (n=340)			Received two doses (n=294)			Received two doses (n=294)			
	n	n	n	RR (95% CI)	p- value	n	RR (95% CI)	p-value	RR (95% CI)	p- value	RR (95% CI)	p-value
Fatigue												
19-35	108	29	31	1.2 [0.8–1.8]	0.463	13	0.9 [0.5–1.6]	0.753	0.6 [0.2–1.8]	0.343	0.9 [0.6–1.5]	0.715
36-60	221	46	51	1.1 [0.8–1.5]	0.660	16	0.4 [0.3–0.7]	0.001	0.3 [0.1–0.8]	0.015	0.5 [0.3–0.9]	0.008
>60	98	7	11	0.8 [0.4–1.9]	0.664	4	0.2 [0.1–0.6]	0.005	0.2 [0.0–1.3]	0.094	0.3 [0.1–0.8]	0.012
Headache												
19-35	131	30	29	1.1 [0.7–1.7]	0.781	14	1.0 [0.6–1.7]	0.853	0.4 [0.1–1.0]	0.060	0.8 [0.5–1.3]	0.381
36-60	192	32	42	1.2 [0.8–1.9]	0.282	24	0.9 [0.6–1.5]	0.660	0.6 [0.3–1.3]	0.206	0.9 [0.6–1.3]	0.624
>60	64	7	9	0.8 [0.3–1.9]	0.590	3	0.2 [0.1–0.6]	0.007	0.4 [0.0–4.5]	0.457	0.3 [0.1–1.0]	0.056
Weakness in arms and legs												
19-35	31	18	13	0.8 [0.4–1.5]	0.499	5	0.6 [0.2–1.5]	0.234	0.8 [0.2–3.2]	0.753	1.2 [0.5–3.0]	0.667
36-60	100	26	34	1.3 [0.8–2.1]	0.280	11	0.5 [0.3–1.0]	0.061	0.5 [0.2–1.3]	0.152	0.8 [0.4–1.5]	0.461
>60	68	7	10	0.8 [0.3–1.8]	0.518	4	0.2 [0.1–0.6]	0.005	0.1 [0.0–0.5]	0.008	0.4 [0.2–1.1]	0.079
Persistent muscle pain												
19-35	31	10	12	1.0 [0.5–2.7]	0.832	6	0.9 [0.3–2.8]	0.862	0.3 [0.0–2.4]	0.247	1.0 [0.4–2.7]	0.962
36-60	70	12	10	1.2 [0.7–2.0]	0.477	9	0.6 [0.3–1.1]	0.109	0.4 [0.1–1.4]	0.146	1.1 [0.6–2.1]	0.670
>60	46	2	4	1.1 [0.3–3.4]	0.921	5	0.2 [0.0–1.0]	0.051	-	-	0.3 [0.1–1.2]	0.097
Loss of concentration												
19-35	30	13	12	1.0 [0.5–2.1]	0.966	5	0.8 [0.3–2.1]	0.624	2.5 [0.2–26.2]	0.457	1.3 [0.5–3.1]	0.617
36-60	39	17	27	1.5 [0.9–2.7]	0.153	6	0.4 [0.2–1.0]	0.061	0.3 [0.3–2.3]	0.232	1.1 [0.5–2.6]	0.795
>60	19	3	5	1.0 [0.3–4.0]	0.989	2	0.3 [0.0–1.5]	0.103	0.6 [0.0–1.9]	0.110	0.7 [0.2–3.1]	0.682
Hair loss												
19-35	27	17	11	0.7 [0.3–1.5]	0.351	4	0.5 [0.2–1.4]	0.166	0.4 [0.1–1.7]	0.188	1.1 [0.4–3.1]	0.826
36-60	42	18	28	1.5 [0.9–2.6]	0.163	4	0.3 [0.1–0.8]	0.014	0.1 [0.0–1.2]	0.070	0.7 [0.3–1.9]	0.475
>60	12	1	1	2.4 [0.3–20.9]	0.421	1	0.4 [0.0–6.0]	0.495	-	-	0.6 [0.1–4.5]	0.605
Sleeping problems												
19-35	33	6	7	1.3 [0.5–3.7]	0.643	3	1.0 [0.3–3.9]	0.981	1.2 [0.2–0.8]	0.872	0.7 [0.2–2.2]	0.523
36-60	88	19	30	1.5 [0.9–2.6]	0.139	8	0.5 [0.2–1.1]	0.092	0.6 [0.1–2.3]	0.423	0.7 [0.3–1.3]	0.246

>60	63	4	5	0.8 [0.2–2.5]	0.620	3	0.3 [0.1–1.1]	0.070	-	-	0.3 [0.1– 1.0]	0.060
Dizziness												
19-35	39	9	8	1.0 [0.4–2.5]	0.963	5	1.1 [0.4–3.2]	0.819	0.5 [0.1–2.3]	0.341	1.0 [0.4– 2.4]	0.945
36-60	75	20	19	0.9 [0.5–1.6]	0.737	6	0.4 [0.2–0.9]	0.023	0.2 [0.1–1.1]	0.070	0.6 [0.3– 1.3]	0.190
>60	38	3	3	0.6 [0.1–2.7]	0.494	1	0.1 [0.0–1.2]	0.071	-	-	0.2 [0.0– 1.3]	0.094
Persistent cough												
19-35	39	10	12	1.3 [0.6–2.9]	0.494	6	1.2 [0.5–3.2]	0.685	1.0 [0.3–3.7]	0.961	1.2 [0.5– 2.6]	0.716
36-60	61	12	10	0.8 [0.4–1.8]	0.575	9	0.9 [0.4–2.1]	0.802	0.8 [0.2–3.9]	0.770	1.1 [0.5– 2.1]	0.840
>60	34	2	4	1.2 [0.2–6.4]	0.819	5	1.0 [0.2–4.8]	0.962	0.1 [0.0–2.8]	0.202	1.0 [0.4– 2.6]	0.943
Shortness of breath												
19-35	22	10	5	0.8 [0.3–2.0]	0.583	5	1.0 [0.4–2.8]	0.974	0.5 [0.1–2.3]	0.360	1.7 [0.7– 4.3]	0.254
36-60	37	13	19	1.3 [0.7–2.7]	0.343	7	0.7 [0.3–1.6]	0.336	-	-	1.4 [0.6– 3.0]	0.428
>60	18	2	3	0.9 [1.2–5.0]	0.880	2	0.4 [0.1–2.4]	0.284	0.1 [0.0–1.8]	0.909	0.8 [0.2– 3.3]	0.738
Recovery from COVID-19												
19-35	NA	71	60	0.9 [0.7–1.1]	0.347	31	0.9 [0.7–1.1]	0.263	0.8 [0.5–1.1]	0.163	NA	NA
36-60	NA	85	92	1.0 [0.8–1.2]	0.836	67	1.0 [0.8–1.3]	0.732	0.9 [0.7–1.3]	0.611	NA	NA
>60	NA	14	38	1.4 [1.0–2.1]	0.088	75	1.7 [1.2–2.4]	0.004	1.7 [0.8–3.5]	0.174	NA	NA

*Adjusted for duration of follow-up and asymptomatic population, n= only participants with symptoms, NA – Not applicable

1

2

3

4

5

6

7

8

Supplementary table 2. Crude and adjusted risk ratios for post COVID symptoms among participants												
			Vaccinated vs unvaccinated (Infected individuals)								Two doses vaccinated + infected vs uninfected	
			Unadjusted analysis						Adjusted analysis*			
Symptoms and age	Uninfected (n=2447)	Unvaccinated (n=317)	Received one dose (n=340)			Received two doses (n=294)			Received two doses (n=294)			
	n	n	n	RR (95% CI)	p-value	n	RR (95% CI)	p-value	RR (95% CI)	p-value	RR (95% CI)	p-value
Fatigue	430	82	93	1.1 [0.8–1.4]	0.667	33	0.4 [0.3–0.6]	0.001	0.4 [0.2–0.7]	0.003	0.6 [0.5–0.9]	0.008
Headache	387	69	80	1.1 [0.8–1.4]	0.590	41	0.6 [0.5–0.9]	0.013	0.5 [0.3–0.9]	0.010	0.9 [0.7–1.2]	0.389
Weakness of limbs	199	51	57	1.0 [0.7–1.5]	0.815	20	0.4 [0.3–0.7]	0.001	0.4 [0.2–0.9]	0.033	0.8 [0.5–1.2]	0.405
Persistent muscle pain	147	24	26	1.2 [0.8–1.8]	0.465	20	0.5 [0.3–0.9]	0.017	0.3 [0.1–0.9]	0.028	0.9 [0.6–1.5]	0.835
Loss of concentration	88	33	44	1.2 [0.8–1.9]	0.315	13	0.4 [0.2–0.8]	0.007	0.6 [0.2–2.1]	0.408	1.2 [0.7–2.1]	0.501
Hair loss	81	36	43	1.1 [0.7–1.7]	0.612	9	0.3 [0.1–0.6]	0.001	0.2 [0.1–0.7]	0.005	0.9 [0.5–1.8]	0.794
Sleeping problems	184	29	42	1.4 [0.9–2.1]	0.189	14	0.5 [0.3–1.0]	0.038	0.5 [0.2–1.6]	0.264	0.6 [0.4–1.1]	0.087
Dizziness	152	32	30	0.9 [0.5–1.4]	0.578	12	0.4 [0.2–0.8]	0.006	0.3 [0.1–1.8]	0.018	0.7 [0.4–1.2]	0.146
Persistent cough	134	24	26	1.0 [0.6–1.7]	0.971	20	0.9 [0.5–1.6]	0.714	0.7 [0.3–1.9]	0.483	1.2 [0.8–1.9]	0.366
Shortness of breath	77	25	29	1.1 [0.7–1.8]	0.764	14	0.6 [0.3–1.1]	0.199	0.2 [0.1–0.9]	0.026	1.5 [0.9–2.6]	0.157
Loss of taste	16	28	20	0.7 [0.4–1.2]	0.150	15	0.6 [0.3–1.1]	0.076	0.5 [0.2–1.3]	0.143	-	-
Chest pains	79	23	24	1.0 [0.6–1.7]	0.922	14	0.7 [0.3–1.3]	0.201	0.7 [0.2–2.1]	0.521	5.2 [3.7–7.2]	0.000
Pins and needles sensation	92	23	31	1.3 [0.7–2.1]	0.387	6	0.3 [0.1–0.7]	0.005	0.1 [0.0–0.7]	0.021	0.5 [0.2–1.2]	0.143
Palpitations	68	19	26	1.3 [0.7–2.3]	0.403	12	0.7 [0.3–1.4]	0.285	0.5 [0.1–2.1]	0.364	6.0 [4.2–8.5]	0.000
Depression and anxiety	62	19	19	0.9 [0.5–1.7]	0.824	17	1.0 [0.5–1.8]	0.912	0.9 [0.4–2.0]	0.824	3.1 [1.9–4.9]	0.000
Abdominal pain	132	22	24	1.0 [0.6–1.8]	0.952	8	0.4 [0.2–0.9]	0.021	0.3 [0.1–1.7]	0.185	2.7 [1.9–3.7]	0.000
Problems with balance	91	21	24	1.1 [0.6–1.9]	0.826	7	0.4 [0.2–0.8]	0.017	0.2 [0.1–1.3]	0.096	-	-
Inability to control body movement	39	18	22	1.1 [0.6–2.1]	0.672	9	0.5 [0.2–1.2]	0.123	0.5 [0.1–2.2]	0.357	7.7[5.0– 11.9]	0.000
Joint pain or swelling	93	20	22	1.0 [0.6–1.8]	0.933	5	0.3 [0.1–0.7]	0.008	0.1[0.0–0.7]	0.023	0.4 [0.2–1.1]	0.077
Loss of smell	17	23	9	0.4 [0.2–0.8]	0.009	9	0.4 [0.2–0.9]	0.025	0.3[0.1–1.3]	0.111	7.3 [3.7–14.5]	0.000
Loss of appetite	58	17	11	0.6 [0.3–1.3]	0.182	12	0.8 [0.4–1.6]	0.458	0.4[0.1–1.2]	0.114	1.7 [0.9–3.2]	0.081
Pain on breathing	25	16	16	0.9 [0.5–1.8]	0.839	8	0.5 [0.2–1.2]	0.146	0.3[0.1–1.2]	0.152	2.7 [1.2–5.6]	0.015
Nausea and vomiting	83	19	11	0.5 [0.3–1.1]	0.096	7	0.4 [0.2–0.9]	0.034	0.1[0.0–1.3]	0.085	0.7 [0.3–1.5]	0.363
Constipation	78	14	12	0.8 [0.4–1.7]	0.561	8	0.6 [0.3–1.4]	0.266	0.7[0.2–2.9]	0.664	0.9 [0.4–1.7]	0.666
Erectile dysfunction	33	12	12	0.9 [0.4–2.0]	0.861	8	0.7 [0.3–1.7]	0.462	0.9 [0.3–2.8]	0.839	2.0 [0.9–4.3]	0.071
Diarrhoea	101	15	11	0.7 [0.3–1.5]	0.329	5	0.4 [0.1–1.0]	0.045	0.3 [0.1–1.3]	0.095	3.3 [2.3–4.7]	0.000

Double vision	26	9	17	1.8 [0.8–3.9]	0.162	3	0.4 [0.1–1.3]	0.122	0.5 [0.4–5.2]	0.535	5.1 [2.8–9.4]	0.000
Problems speaking or communicating	18	10	15	1.4 [0.6–3.1]	0.403	3	0.3 [0.1–1.2]	0.084	0.4 [0.0–3.5]	0.391	1.4 [0.4–4.7]	0.598
Weight loss	25	14	6	0.4 [0.2–1.0]	0.057	8	0.6 [0.3–1.4]	0.266	0.3 [0.1–1.5]	0.152	2.7 [1.2–5.9]	0.015
Tremor / shakiness	45	8	11	1.3 [0.5–3.1]	0.588	8	1.1 [0.4–2.8]	0.879	0.1 [0.2–7.0]	0.908	1.5 [0.7–3.1]	0.301
Problems passing urine	34	8	6	0.7 [0.2–2.0]	0.503	2	0.3 [0.1–1.3]	0.096	-	-	3.4 [1.9–6.3]	0.000
Loss of sensation, one side of the body	16	6	7	1.1 [0.4–3.2]	0.879	2	0.4 [0.1–1.8]	0.208	0.4 [0.0–5.0]	0.495	1.0 [0.2–4.5]	0.958
Skin lumps or rashes	14	6	5	0.8 [0.2–2.5]	0.674	2	0.4 [0.1–1.8]	0.208	-	-	1.2 [0.3–5.2]	0.818
Problems swallowing or chewing	18	4	5	1.2 [0.3–4.3]	0.818	3	0.8 [0.2–3.6]	0.780	-	-	9.2 [4.9–17.2]	0.000
Blood clots in veins	0	4	5	1.2 [0.3–4.3]	0.801	3	1.0 [0.2–4.2]	0.955	-	-	-	-
Kidney problems	0	5	5	0.9 [0.3–3.2]	0.925	2	0.5 [0.1–2.6]	0.415	0.7[0.1–4.2]	0.693	-	-
Fainting / blackouts	0	2	4	1.9 [0.3–10.1]	0.470	4	2.2 [0.4–11.7]	0.373	0.4[0.0–4.3]	0.448	-	-
Seizures / fits	11	3	4	1.2 [0.3–5.5]	0.775	3	1.1 [0.2–5.3]	0.926	0.4[0.0–4.3]	0.421	2.3 [0.6–8.1]	0.206
Heart attack & stroke	0	0	2	-	-	1	-	-	-	-	-	-

*Adjusted for duration of time from first reporting symptoms, age and symptoms at infection, NA – Not applicable

9

10

11

12

13

14

15